Expression of CXCR4 in Patients With Systemic Lupus Erythematosus

• Conditions: Systemic Lupus Erythematosus

• Registration Number: NCT04799730
• Lead Sponsor: Sohag University

Brief Summary

The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.

Detailed Description

Detection of CXCR4 (CD184) expression on CD19+ B cells by flow cytometry in patients of SLE, comparing its level in the development of lupus activity and pathogenic process of SLE internal organ involvement/ mucocutaneus and/or musculoskeletal involvement. Identify this correlation will be useful for clarifying other accessory factors to improve the diagnosis, better treatment strategy, follow up as well as prognosis for these patients

Study Timeline

• Status Verified: 2021-03
• Study First Submitted: 2021-03-14
• Study First Submitted QC: 2021-03-14
• Last Update Submitted: 2021-03-14
• Study First Posted: 2021-03-16
• Last Update Posted: 2021-03-16
• Study Start: 2021-05
• Primary Completion: 2021-11
• Study Completion: 2022-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Confirmed SLE patients diagnosed and fulfilled the SLE classification criteria according to the 2019 ACR/EULAR classification criteria for SLE (Aringer et al., 2019)
• Willing and agreed to be included in the study.

Exclusion Criteria

• Childhood SLE.
• SLE-patients will refuse to consent to this study.
• Other autoimmune diseases.
• Known or suspected malignancies, especially B cell lymphoma.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changes in the expression of CD184(CXCR4) expression in circulating B cells	6 months	Flow cytometry analysis of chemokine receptor (CXCR4):Human peripheral-blood mononuclear cells (PBMCs) labeling with CXCR4 antibody will be performed in the same day after taking blood samples and subsequent measurement of the CXCR4 mean fluorescence intensity (MFI) by flow cytometry. MFI of the anti-chemokine receptor (CXCR4) staining will be calculated according to statistical thresholds set in reference to staining with negative control antibodies. The patient's CXCR4 on CD19+ B cells expression or mean MFI will be further compared to the MFI of the simultaneously performed age-matched controls samples and other subgroups of SLE patients.